Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Neuro-Oncology
Published in: Journal of Neuro-Oncology 3/2017

01-05-2017 | Clinical Study

Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution

Authors: M. Azoulay, F. Santos, G. Shenouda, K. Petrecca, A. Oweida, M. C. Guiot, S. Owen, V. Panet-Raymond, L. Souhami, Bassam S. Abdulkarim

Published in: Journal of Neuro-Oncology | Issue 3/2017

Login to get access

Abstract

The optimal management of recurrent glioblastoma (GBM) has yet to be determined. We aim to assess the benefits of re-operation and salvage therapies (chemotherapy and/or re-irradiation) for recurrent GBM and to identify prognostic factors associated with better survival. All patients who underwent surgery for GBM between January 2005 and December 2012 followed by adjuvant radiotherapy, and who developed GBM recurrence on imaging were included in this retrospective study. Univariate and multivariate analysis was performed using Cox models in order to identify factors associated with overall survival (OS). One hundred and eighty patients treated to a dose of 60 Gy were diagnosed with recurrent GBM. At a median follow-up time of 6.2 months, the median survival (MS) from time of recurrence was 6.6 months. Sixty-nine patients underwent repeat surgery for recurrence based on imaging. To establish the benefits of repeat surgery and salvage therapies, 68 patients who underwent repeat surgery were matched to patients who did not based on extent of initial resection and presence of subventricular zone involvement at recurrence. MS for patients who underwent re-operation was 9.6 months, compared to 5.3 months for patients who did not have repeat surgery (p < 0.0001). Multivariate analysis in the matched pairs confirmed that repeat surgery with the addition of other salvage treatment can significantly affect patient outcome (HR 0.53). Re-operation with additional salvage therapies for recurrent GBM provides survival prolongation at the time of progression.
Literature
1.
Minniti G et al (2010) Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol 97(3):377–381CrossRefPubMed
2.
Batchelor TT et al (2013) Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 31(26):3212–3218CrossRefPubMedPubMedCentral
3.
Wick W et al (2010) Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28(7):1168–1174CrossRefPubMedPubMedCentral
4.
Reardon DA et al (2012) Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma. J Neurooncol 107(1):155–164CrossRefPubMed
5.
Wong ET et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17(8):2572–2578CrossRefPubMed
6.
Brandes AA et al (2004) Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 22(23):4779–4786CrossRefPubMed
7.
Kappelle AC et al (2001) PCV chemotherapy for recurrent glioblastoma multiforme. Neurology 56(1):118–120CrossRefPubMed
8.
Friedman HS et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733–4740CrossRefPubMed
9.
Kreisl TN et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740–745CrossRefPubMed
10.
Vredenburgh JJ et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722–4729CrossRefPubMed
11.
12.
13.
Niyazi M et al (2012) Irradiation and bevacizumab in high-grade glioma retreatment settings. Int J Radiat Oncol Biol Phys 82(1):67–76CrossRefPubMed
14.
Ciammella P et al (2013) Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience. Radiat Oncol 8(1):222CrossRefPubMedPubMedCentral
15.
Park KJ et al (2012) Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case-control study. J Neurooncol 107(2):323–333CrossRefPubMed
16.
Cuneo KC et al (2012) Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 82(5):2018–2024CrossRefPubMed
17.
Gutin PH et al (2009) Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75(1):156–163CrossRefPubMedPubMedCentral
18.
Combs SE et al (2005) Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme. J Neurooncol 74(2):167–171CrossRefPubMed
19.
Nieder C et al (2008) Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma. Am J Clin Oncol 31(3):300–305CrossRefPubMed
20.
McKenzie JT et al (2013) Hypofractionated stereotactic radiotherapy for unifocal and multifocal recurrence of malignant gliomas. J Neurooncol 113(3):403–409CrossRefPubMed
21.
Ruben JD et al (2006) Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 65(2):499–508CrossRefPubMed
22.
Hall WA et al (1995) Stereotactic radiosurgery for recurrent malignant gliomas. J Clin Oncol 13(7):1642–1648CrossRefPubMed
23.
Cho KH et al (1999) Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys 45(5):1133–1141CrossRefPubMed
24.
Combs SE et al (2005) Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 23(34):8863–8869CrossRefPubMed
25.
Ammirati M et al (1987) Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 21(5):607–614CrossRefPubMed
26.
Harsh, G.R.t. et al (1987) Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery 21(5):615–621CrossRefPubMed
27.
De Bonis P et al (2013) The influence of surgery on recurrence pattern of glioblastoma. Clin Neurol Neurosurg 115(1):37–43CrossRefPubMed
28.
29.
Park CK et al (2013) A practical scoring system to determine whether to proceed with surgical resection in recurrent glioblastoma. Neuro Oncol 15(8):1096–1101CrossRefPubMedPubMedCentral
30.
Ryken TC et al (2014) The role of cytoreductive surgery in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline. J Neurooncol 118(3):479–488CrossRefPubMed
31.
Barbagallo GM, Jenkinson MD, Brodbelt AR (2008) ‘Recurrent’ glioblastoma multiforme, when should we reoperate? Br J Neurosurg 22(3):452–455CrossRefPubMed
32.
De Bonis P et al (2013) The impact of repeated surgery and adjuvant therapy on survival for patients with recurrent glioblastoma. Clin Neurol Neurosurg 115(7):883–886CrossRefPubMed
33.
Mandl ES et al (2008) Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy. Surg Neurol 69(5):506–509 (discussion 509).CrossRefPubMed
34.
Barker FG 2nd et al (1998) Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 42(4):709–720 (discussion 720-723).CrossRefPubMed
35.
Keles GE et al (2004) Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. J Neurosurg 100(1):41–46CrossRefPubMed
36.
Butowski NA, Sneed PK, Chang SM (2006) Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin Oncol 24(8):1273–1280CrossRefPubMed
37.
Bloch O et al (2012) Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J Neurosurg 117(6):1032–1038CrossRefPubMed
38.
Quick J et al (2014) Benefit of tumor resection for recurrent glioblastoma. J Neurooncol 117(2):365–372CrossRefPubMed
39.
Chaichana KL et al (2013) Multiple resections for patients with glioblastoma: prolonging survival. J Neurosurg 118(4):812–820CrossRefPubMed
Metadata
Title
Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution
Authors
M. Azoulay
F. Santos
G. Shenouda
K. Petrecca
A. Oweida
M. C. Guiot
S. Owen
V. Panet-Raymond
L. Souhami
Bassam S. Abdulkarim
Publication date
01-05-2017
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 3/2017
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-017-2383-2

Other articles of this Issue 3/2017

Journal of Neuro-Oncology 3/2017 Go to the issue

Laboratory Investigation

Overexpression of NIMA-related kinase 2 is associated with poor prognoses in malignant glioma

Letter to the Editor

Tumor types, breast tumor subtypes and extension of systemic disease may influence outcome in cancer patients with brain metastases

Clinical Study

Incidence of CNS tumors in Appalachian children

Clinical Study

Neutrophil–lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival

Letter to the Editor

Glioblastoma recurrence, progression, and dissemination as a purely subdural gliosarcoma

Clinical Study

Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan